Engineers Gate Manager LP Sells 64,517 Shares of Charles River Laboratories International, Inc. $CRL

Posted by Francis Steltz on Sep 12th, 2026

Engineers Gate Manager LP reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 68.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,267 shares of the medical research company’s stock after selling 64,517 shares during the quarter. Engineers Gate Manager LP’s holdings in Charles River Laboratories International were worth $6,637,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Empirical Finance LLC grew its position in Charles River Laboratories International by 4.4% in the 2nd quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company’s stock worth $333,000 after purchasing an additional 62 shares during the last quarter. Glenmede Trust Co. NA raised its position in shares of Charles River Laboratories International by 2.8% during the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after buying an additional 73 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Charles River Laboratories International by 1.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after buying an additional 80 shares during the last quarter. Syon Capital LLC lifted its stake in shares of Charles River Laboratories International by 2.4% in the second quarter. Syon Capital LLC now owns 3,547 shares of the medical research company’s stock valued at $804,000 after buying an additional 83 shares during the period. Finally, Advisory Services Network LLC lifted its stake in shares of Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after buying an additional 83 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Barclays restated an “overweight” rating and set a $300.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Piper Sandler set a $300.00 price objective on Charles River Laboratories International in a report on Monday, August 10th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, TD Cowen upped their target price on Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Eleven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.69.

Read Our Latest Report on Charles River Laboratories International

Charles River Laboratories International Stock Performance

NYSE CRL opened at $278.02 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $303.30. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The stock has a market cap of $13.27 billion, a P/E ratio of -57.32, a PEG ratio of 2.68 and a beta of 1.40. The company’s 50-day simple moving average is $260.17 and its 200 day simple moving average is $205.58.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total value of $1,819,350.00. Following the transaction, the chief executive officer directly owned 36,013 shares in the company, valued at $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president owned 30,051 shares in the company, valued at approximately $7,788,017.16. This trade represents a 12.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 165,990 shares of company stock valued at $42,606,388. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

(Free Report)

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.